May 01, 2019
3 min watch
Save
This article is more than 5 years old. Information may no longer be current.
VIDEO: 36-month Yutiq data released
VANCOUVER, British Columbia — EyePoint Pharmaceuticals CEO Nancy Lurker discusses 36-month safety and efficacy data for Yutiq (fluocinolone acetonide intravitreal implant 0.18 mg), released at the Association for Research in Vision and Ophthalmology meeting here.
The uveitis recurrence rate was 56.3% in Yutiq-treated eyes compared with 92.9% in sham-treated eyes. Eyes treated with Yutiq needed adjunctive intraocular or periocular medications 19.5% of the time, whereas 69% of sham-treated eyes needed rescue.
Disclosure: Lurker reports she is CEO of EyePoint Pharmaceuticals.
Read more from Association for Research in Vision and Ophthalmology
View allJuly 11, 2024
2 min watch
Save
July 08, 2024
1 min read
Save
July 01, 2024
1 min watch
Save
June 21, 2024
1 min read
Save
June 20, 2024
1 min read
Save
June 19, 2024
1 min read
Save
June 16, 2024
5 min watch
Save
June 12, 2024
1 min watch
Save
June 10, 2024
2 min watch
Save